CD8A and infection: The above results reveal that the immune response elicited by the Ad-liNS1/NS2 vaccine (anti-NS1 antibodies and CD8 T cell response) takes more time to affect the course of the infection, but nevertheless, eventually manages to control ZIKV replication in the brain.